eRF3a Antibodies

Santa Cruz Biotechnology provides a broad selection of eRF3a Antibodies for investigating eRF3a's role in cellular processes. eRF3a Antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). eRF3a, or eukaryotic release factor 3a, plays a critical role in the termination of protein synthesis by facilitating the release of newly synthesized polypeptides from the ribosome. eRF3a maintains the fidelity of translation and participates in various cellular stress responses. Research has shown that eRF3a influences gene expression regulation and may have implications in diseases such as cancer. Scientists worldwide rely on eRF3a monoclonal antibodies to advance their understanding of translation termination mechanisms. Ongoing studies continue to reveal new aspects of eRF3a function in cellular homeostasis and disease progression. Research utilizing Santa Cruz Biotechnology monoclonal antibodies contributes to expanding scientific knowledge about eRF3a's role in fundamental biological processes.